3^rd World Congress on Gynaecology, Obstetrics & Reproductive Health

After the successful completion of two remarkable editions, Times Scientific Group is delighted to announce the 3rd World Congress on Gynaecology, Obstetrics & Reproductive Health – Gynaec and Obstetrics 2026, scheduled to take place on December 03–04, 2026 in Osaka, Japan.

This international gathering will bring together leading researchers, healthcare professionals, academicians, and industry experts to exchange ideas, share recent innovations, and advance the global dialogue in women’s health, gynecology, obstetrics, and reproductive medicine.

Gynaec and Obstetrics 2026 aims to serve as a multidisciplinary platform to explore the latest developments in Gynaecology, Obstetrics & Reproductive Health, while addressing critical areas such as women’s health and nursing, reproductive and sexual health, and maternal-fetal medicine.

The conference will delve into topics ranging from pediatric and adolescent gynecology to pregnancy and childbirth, including advances in perinatology, neonatology, and midwifery, with a strong emphasis on integrated care. Discussions will also encompass fetal and maternal medication, the management of abortion and miscarriage, and the prevention and diagnosis of birth defects.

With growing global attention on reproductive choices, the event will highlight modern approaches to family planning, explore male and female contraception innovations, and review the use of medicated intrauterine devices. Fundamental biological processes such as the menstrual cycle and ovulation, and their disorders, will be covered alongside breakthroughs in reproductive immunology and implantation science.

Given the rising incidence of infertility, both female and male infertility—including causes, diagnostics, and treatment—will be key themes, with focused sessions on PCOD & PCOS, endometriosis, and other gynecological disorders. The agenda will further explore urogynaecology, menopause management, and advances in sexual medicine and the treatment of sexually transmitted infections.

Cutting-edge research in gynecological oncology, including breast and ovarian cancer, will be presented, alongside developments in cosmetic and reconstructive gynecology. There will also be extensive coverage of fertility surgery, IVF treatment, and emerging fertilization techniques, supported by the latest progress in assisted reproductive technologies (ART).

In addition, the conference will spotlight innovations in embryology, laboratory sciences, and reproductive genetics and genomics, complemented by sessions on ultrasound and genetic diagnostics, and the role of radiation therapy in treatment planning. The importance of evidence-based medicine will be addressed through updates on clinical trials, as well as deep dives into epidemiology, pathophysiology, and the lingering impacts of COVID-19 on reproductive healthcare systems.

Participants will also have the opportunity to explore instructive and unusual case reports, allowing for the exchange of unique clinical experiences and solutions to real-world challenges.

With its comprehensive agenda and commitment to scientific excellence, Gynaec and Obstetrics 2026 promises to be a premier event for advancing knowledge, fostering international collaboration, and shaping the future of gynecology and reproductive health.

Why to Attend Our 3^rd World Congress on Gynaecology, Obstetrics & Reproductive Health ?
This conference is a must-attend event for clinicians, researchers, reproductive health professionals, policymakers, and students who are passionate about advancing Gynaecology, Obstetrics & Reproductive Health care worldwide. Here’s what makes this event truly exceptional:

Cutting-Edge Research and Innovation:
Hear directly from world-renowned experts presenting the latest findings, clinical advancements, and groundbreaking therapies that are transforming women's health, maternal care, and reproductive medicine.

Comprehensive Learning Opportunities:
Attend keynote speeches, panel discussions, hands-on workshops, and poster sessions covering a wide range of topics including high-risk pregnancies, infertility treatments, fetal medicine, reproductive endocrinology, and gynecologic oncology.

Networking and Collaboration:
Engage with a global community of professionals from diverse backgrounds. Build relationships that foster cross-border collaborations, interdisciplinary research, and long-term partnerships beyond the conference.

Professional Development:
Earn continuing education credits, acquire new clinical skills, and enhance your professional credentials by participating in expert-led sessions, certification programs, and career development tracks.

Patient-Centered Focus:
Discover innovative approaches that prioritize patient safety, positive birth outcomes, fertility success, and overall reproductive well-being—empowering you to make a lasting impact in your clinical practice or research initiatives.

Platform for Young Researchers:
The congress provides a valuable stage for early-career scientists and medical professionals to present their work, gain visibility, receive expert feedback, and connect with mentors and potential collaborators.

Visa & Travel Assistance:

All registered international participants will receive an official invitation letter to with their visa application. We recommend submitting applications early to ensure timely processing and smooth travel. Register early for the conference to secure your spot and enjoy all sessions, networking opportunities, and conference benefits without any hassle.

Gynecology market analysis in the US,Europe & Asia for 2024-2025:

United States / North America
In 2024, North America held over 40% of the global gynecology drugs market, valued at approximately USD 25.8 billion. The market is expected to grow at a CAGR of 3.2% from 2024 to 2031.

Europe
Europe accounted for over 30% of the global gynecology drugs market in 2024, valued at approximately USD 19.4 billion. The market is projected to grow at a CAGR of 5.0% from 2024 to 2031.

Asia
Asia-Pacific held around 23% of the global gynecology drugs market in 2024, valued at approximately USD 14.8 billion. The market is expected to grow at a CAGR of 7.0% from 2024 to 2031.